Moscow to attract 109 billion rubles to pharmaceutical industry by 2030

Vladimir Efimov, Deputy Mayor of Moscow for Urban Development Policy and Construction, spoke about the construction of a new pharmaceutical enterprise in the capital with an investment volume of 13 billion rubles. In the Severny district, a plot of land of more than 15.5 hectares has been allocated, a lease agreement has been concluded for 5 years, during which it is planned to build a facility with a total area of ​​109 thousand square meters, including a single center for strategic and operational planning of production activities, as well as departments responsible for studying the prospects for the release of new innovative drugs, development and transfer of technologies.

In addition, the volume of investments by residents of the Technopolis Moscow SEZ cluster of enterprises, which is a key driver for the development of the pharmaceutical industry in Moscow, has already exceeded 55 billion rubles, and by 2030 investments should grow to 149.6 billion rubles. The total area of ​​existing production facilities exceeds 145 thousand square meters, employing about 2.9 thousand people.

Since 2022, it has united 14 drug manufacturers and developers, eight of which have already entered the market. Among the achievements are the first Russian drug for multiple sclerosis, a remedy for Bechterew's disease, antitumor drugs, as well as a domestic analogue of Ozempic for the treatment of type 2 diabetes.

According to the results of 2024, Moscow ranks second in Russia in terms of revenue in the pharmaceutical industry, but by 2030 it plans to become a leader: the projected revenue will be 230 billion rubles. At the moment, more than 300 pharmaceutical enterprises operate in the capital, employing about 30 thousand people.

Over the past five years, the volume of production of medicines and medical devices in Moscow has increased by 2.8 times and reached 154 billion rubles. In January-July 2025, enterprises increased the production of drugs for the treatment of diseases of the digestive tract by 6.5 times, drugs for the cardiovascular system - by 2.3 times, drugs for the respiratory system - by 2.1 times, antitumor agents and immunomodulators - by 1.6 times.

Support for the pharmaceutical industry has been a priority area of ​​state policy at the federal level for several years now. In 2023, the Pharma-2030 strategy was approved , which envisages the development of a full production cycle - from development to the launch of drugs on the market. According to the Ministry of Industry and Trade, the program pays special attention to compensating part of the costs of clinical trials of innovative drugs, which should increase the competitiveness of Russian companies and speed up the launch of drugs on the market.

In May 2025, Russian President Vladimir Putin held a meeting with members of the All-Russian public organization "Business Russia", the main topic of which was ensuring balanced economic development in the context of structural transformation. Among other things, topics of offset contracts, government support measures for the pharmaceutical industry, and equipping clinical bases with drugs were discussed. How the discussion went is in the Vademecum review .